Bellicum Pharmaceuticals is developing a therapeutic vaccine for late-stage prostate cancer. The start-up believes that one of the reasons vaccines have floundered in the clinic may be negative feedback loops that desensitize the vaccine before it's had a chance to work. Bellicum's autologous vaccine is designed to avoid that. Its dimerizer agent is injected 24 hours after the vaccine, giving the dendritic cells time to migrate to draining lymph nodes before activation. When therapeutic vaccine cells are stimulated ex-vivo, they begin releasing key cytokines, such as IL-12, immediately.
6400 Fannin Street
Suite 2300
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
The number of viable biotech companies exploiting a particular technology should be limited by intellectual property but the number of biotech IPOs exploiting that same technology always seems greater than those with freedom to operate.
Bimagrumab added to Wegovy increased weight loss and preserved muscle mass, but analysts want to see more safety and efficacy results from a combination with Zepbound.
As it races AstraZeneca’s baxdrostat to market, Mineralys plans to file an NDA later this year, backed by strong efficacy and safety data across four trials.
